Economic Burden of Disease Progression Among Transplant Eligible Multiple Myeloma Patients Who Have Received at Least One Line of Therapy in the US

被引：1
|
作者：
Fonseca, Rafael [1 ]
Hagiwara, May [2 ]
Panjabi, Sumeet [3 ]
Yucel, Emre [4 ]
Buchanan, Jacqueline [5 ]
Delea, Thomas [6 ]
机构：
[1] Mayo Clin, Phoenix, AZ USA
[2] Policy Anal Inc, Brookline, ME USA
[3] Amgen Inc, Thousand Oaks, CA 91320 USA
[4] Amgen Inc, Newbury Pk, CA USA
[5] Amgen Inc, San Francisco, CA USA
[6] Policy Anal Inc, Brookline, MA USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-123743
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2211
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US
    Rafael Fonseca
    May Hagiwara
    Sumeet Panjabi
    Emre Yucel
    Jacqueline Buchanan
    Thomas Delea
    [J]. Blood Cancer Journal, 11
  • [2] Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US
    Fonseca, Rafael
    Hagiwara, May
    Panjabi, Sumeet
    Yucel, Emre
    Buchanan, Jacqueline
    Delea, Thomas
    [J]. BLOOD CANCER JOURNAL, 2021, 11 (02)
  • [3] Burden of Disease Progression in Patients with Multiple Myeloma Who Have Received at Least One Line of Therapy in the US
    Hagiwara, May
    Delea, Thomas
    Panjabi, Sumeet
    Yucel, Emre
    Fonseca, Rafael
    [J]. BLOOD, 2018, 132
  • [4] ECONOMIC EVALUATION OF LENALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA IN WALES IN PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
    Deniz, H. B.
    Ishak, K. J.
    Edwards, D. R.
    Shearer, A.
    Dale, P.
    Caro, J. J.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 320 - 321
  • [5] Economic evaluation of lenalidomide for the treatment of multiple myeloma in Scotland in patients who have received one prior therapy
    Deniz, B.
    Ishak, K. J.
    Shearer, A.
    Dale, P.
    Caro, J. J.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 29 - 30
  • [6] Economic evaluation of lenolidomide use for multiple myeloma in Scotland in patients who have received one prior therapy
    Deniz, B.
    Ishak, K. J.
    Shearer, A.
    Dale, P.
    Caro, J. J.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A156 - A156
  • [7] Burden of disease progression in patients with multiple myeloma in the US
    Hagiwara, May
    Panjabi, Sumeet
    Delea, Tom
    Yucel, Emre
    Fonseca, Rafael
    [J]. LEUKEMIA & LYMPHOMA, 2020, 61 (01) : 47 - 55
  • [8] A COMPREHENSIVE COST-EFFECTIVENESS ANALYSIS OF LENALIDOMIDE FOR MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
    Felix, J.
    Almeida, J.
    Vandewalle, B.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A218 - A218
  • [9] The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy
    Tzogani, Kyriaki
    Camarero Jimenez, Jorge
    Garcia, Isabel
    Sancho-Lopez, Arantxa
    Martin, Marc
    Moreau, Alexandre
    Demolis, Pierre
    Salmonson, Tomas
    Bergh, Jonas
    Laane, Edward
    Ludwig, Heinz
    Gisselbrecht, Christian
    Pignatti, Francesco
    [J]. ONCOLOGIST, 2017, 22 (11): : 1339 - 1346
  • [10] European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
    Tzogani, Kyriaki
    Florez, Beatriz
    Markey, Greg
    Caleno, Mariapaola
    Olimpieri, Odoardo Maria
    Melchiorri, Daniela
    Hovgaard, Doris Johanna
    Sarac, Sinan Bardakci
    Penttila, Karri
    Lapvetelainen, Tuomo
    Salmonson, Tomas
    Bergh, Jonas
    Gisselbrecht, Christian
    Pignatti, Francesco
    [J]. ESMO OPEN, 2019, 4 (05)
12345